# GRIFOLS

**Grifols, S.A.**

Avinguda de la Generalitat 152-158
08174 Sant Cugat del Vallès
Barcelona - ESPAÑA

Tel. [34] 935 710 500
Fax [34] 935 710 267

www.grifols.com

Pursuant to the provisions of article 227 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("**Grifols**") hereby informs about the following

## OTHER RELEVANT INFORMATION

Grifols has executed share purchase arrangements with the South Korean based GC Pharma (Group) ("**GC Pharma**") and other investors for the purchase of a plasma fractionation facility and two purification facilities located in the city of Montreal, Canada (together, the "**Facilities**"), and 11 plasma collection centres located in the United States (the "**Collection Centres**"), for a total consideration of US$460M (the "**Transaction**"), on a debt free basis.

No additional financing will be required. Upon the consummation of the Transaction certain net worth, working capital and cash targets have been guaranteed.

The Facilities are currently in the process of obtaining needed licenses and regulatory approvals by competent health authorities for the manufacturing of plasma-derived products. When licensed and approved, Grifols will become the only commercial manufacturer of plasma products in Canada, with a fractionation capacity of 1.5 M litres.

Grifols plans to be ready to manufacture IVIG and Albumin in the Facilities to supply the Canadian market starting in 2023.

The Collection Centres achieved a collection volume of 350,000 litres of plasma in 2019.

Upon the consummation of the Transaction, and by means of a plasma supply agreement, Grifols has also committed to supplying certain output of plasma arising out of the Collection Centres to GC Pharma for a 24-month period.

The consummation of the Transaction is subject to regulatory approvals and is expected to close prior to the end of 2020.

In Barcelona, on 20 July 2020

Nuria Martín Barnés
Secretary to the Board of Directors